Home > Request Information
Title:
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
* Company:
* Country:
* Name:
Job Title:
* Tel:
Fax:
* E-mail:
Message:
Verification Code:
refresh